Psivant Therapeutics Funding: $50M Raised, Series A (2024)
Psivant Therapeutics is a Biotech company based in Boston. It has raised $50M in total funding. Latest round: Series A.
Psivant Therapeutics funding overview
Psivant Therapeutics is a Biotech company based in Boston. Psivant Therapeutics has raised $50M in total disclosed funding. That places its disclosed total in the $25M–$100M range. Its most recent disclosed round is a Series A announced in March 2024. The round record for Psivant Therapeutics runs through 2024; nothing later has been disclosed. Investors on record include Lightstone Ventures, Samsara BioCapital, Roivant, YK Bioventures, Eurofarma Ventures. 5 distinct backers are named across the disclosed rounds.
Frequently asked about Psivant Therapeutics funding
How much has Psivant Therapeutics raised?
Psivant Therapeutics has raised $50M in total disclosed funding across the rounds on record.
Who has invested in Psivant Therapeutics?
Lightstone Ventures, Samsara BioCapital, Roivant, YK Bioventures, Eurofarma Ventures are named among the investors backing Psivant Therapeutics.
What was the latest Psivant Therapeutics funding round?
The most recent disclosed round is a Series A, announced in March 2024.
Where is Psivant Therapeutics based?
Psivant Therapeutics is based in Boston.
What sector does Psivant Therapeutics operate in?
Psivant Therapeutics is tracked under Biotech from Boston, with $50M in disclosed funding.
When did Psivant Therapeutics last raise?
The last disclosed Psivant Therapeutics round closed in March 2024 at Series A.
Psivant Therapeutics totals reflect disclosed capital only — undisclosed extensions and secondaries are excluded. Use the related Biotech companies in Boston below to benchmark round size and investor mix.
